Bioorganic & Medicinal Chemistry Letters 24 (2014) 4466-4471

Contents lists available at ScienceDirect



Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl



Facile synthesis of SSR180575 and discovery of 7-chloro-*N*,*N*,5trimethyl-4-oxo-3(6-[¹⁸F]fluoropyridin-2-yl)-3,5-dihydro-4*H*pyridazino[4,5-*b*]indole-1-acetamide, a potent pyridazinoindole ligand for PET imaging of TSPO in cancer



Yiu-Yin Cheung^a, Michael L. Nickels^{a,b}, Dewei Tang^{a,b}, Jason R. Buck^{a,b}, H. Charles Manning^{a,b,c,d,e,f,*}

^a Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical Center, Nashville, TN 37232, United States

^b Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN 37232, United States

^c Program in Chemical and Physical Biology, Vanderbilt University Medical Center, Nashville, TN 37232, United States

^d Vanderbilt-Ingram Cancer Center (VICC), Vanderbilt University Medical Center, Nashville, TN 37232, United States

^e Department of Biomedical Engineering, Vanderbilt University, Nashville, TN 37232, United States

^f Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN 37232, United States

ARTICLE INFO

Article history: Received 28 May 2014 Revised 29 July 2014 Accepted 31 July 2014 Available online 8 August 2014

Keywords: TSPO Glioma PET Fluorine-18 SSR180575

ABSTRACT

A novel synthesis of the translocator protein (TSPO) ligand 7-chloro-*N*,*N*,5-trimethyl-4-oxo-3-phenyl-3, 5-dihydro-4*H*-pyridazino[4,5-*b*]indole-1-acetamide (SSR180575, **3**) was achieved in four steps from commercially available starting materials. Focused structure-activity relationship development about the pyridazinoindole ring at the N3 position led to the discovery of 7-chloro-*N*,*N*,5-trimethyl-4-oxo-3(6-fluoro-pyridin-2-yl)-3,5-dihydro-4*H*-pyridazino[4,5-*b*]indole-1-acetamide (**14**), a novel ligand of comparable affinity. Radiolabeling with fluorine-18 (¹⁸F) yielded 7-chloro-*N*,*N*,5-trimethyl-4-oxo-3(6-[¹⁸F]fluoropyridin-2-yl)-3,5-dihydro-4*H*-pyridazino[4,5-*b*]indole-1-acetamide ([¹⁸F]-**14**) in high radiochemical yield and specific activity. In vivo studies of [¹⁸F]-**14** revealed this agent as a promising probe for molecular imaging of glioma.

© 2014 Elsevier Ltd. All rights reserved.

There exists a continuing demand for the development and validation of improved imaging biomarkers of cancer. Such biomarkers may aid in cancer diagnosis, predict clinical outcome, and quantify response to therapeutic intervention. Imaging biomarkers of glioma are limited and routinely include magnetic resonance imaging (MRI), computed tomography (CT), and less frequently. positron emission tomography (PET). Of these, PET may be the most suitable given its exquisite sensitivity, quantitative nature, and ability to characterize the molecular basis of the tumor. For most oncology studies, 2-deoxy-2-[18F]fluoroglucose ([18F]FDG) is commonly utilized, as this tracer reflects glucose metabolism, which is usually elevated in cancer cells.¹ However, relatively high glucose uptake in normal brain results in poor tumor-to-background ratios that can confound glioma detection. Moreover, [¹⁸F]FDG uptake can be affected by a myriad of tangential metabolic processes. This has led many groups to evaluate other PET tracers of metabolism in this setting, including amino acid-based PET probes such as [¹¹C]MET,² [¹⁸F]FET,³ and [¹⁸F]FDOPA.⁴ While these probes can accumulate in tissues that exhibit enhanced

amino acid transport,^{5–7} they can be hampered by nonspecific accumulation.⁶ Thus, there remains a need to develop and validate additional PET imaging biomarkers suitable for glioma detection and characterization.

We have explored translocator protein (TSPO) expression as a target for molecular imaging of cancer with PET.^{8–13} TSPO, formerly the peripheral benzodiazepine receptor (PBR), is an 18 kDa protein that takes part in a wide breadth of cellular processes, including cell proliferation, apoptosis, steroid biosynthesis, and cholesterol metabolism.¹⁴ Though TSPO has historically been leveraged as a PET biomarker in neuroinflammation,^{15–17} its elevated expression has also been reported in many types of cancer.¹⁸ This overexpression in tumors has been reported to correlate with disease progression and diminished survival and can be indicative of aggressive and potentially metastatic tumors.¹⁸ Within this context, our laboratory has investigated the use of TSPO PET ligands to image colon cancer,⁸ breast cancer,⁹ and glioma,^{12,13,19} as these agents could potentially serve as useful cancer imaging biomarkers. Moreover, on a mechanistic level, we have utilized TSPO molecular imaging probes to visualize colon cancers arising in genetically engineered mice with aberrant $Tgf\beta$ signaling,⁸ as well as tumors arising in

^{*} Corresponding author.

mice following loss of *Apc* function.²⁰ These studies suggest the potential importance TSPO PET agents to detect key molecular events in oncology and to possibly serve as companion diagnostics alongside targeted inhibitors of these pathways.

We recently reported the first utilizations of two TSPO-specific PET ligands for quantitative assessment of TSPO expression in preclinical glioma, the aryloxyanilide N-[¹⁸F]fluoroacetyl-N-(2,5dimethoxybenzyl)-2-phenoxyaniline ([¹⁸F]PBR06, [¹⁸F]-1),¹¹ and pyrazolopyrimidine N,N-diethyl-2-(2-(4-(2-[¹⁸F]fluoroeththe oxy)phenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide ([¹⁸F]DPA-714, [¹⁸F]-2a)¹² (Fig. 1). Through focused library synthesis and structure-activity relationship (SAR) development of the 5.6.7-substituted pyrazolopyrimidine scaffold of [¹⁸F]-2a, we developed 2-(5,7-diethyl-2-(4-(2-[¹⁸F]fluoroethoxy)phenyl)pyrazolo[1.5-*a*]pyrimidin-3-yl)-*N*.*N*-diethylacetamide $([^{18}F]-2b]$ [¹⁸F]VUIIS1008), a novel and highly potent TSPO PET ligand exhibiting a 36-fold enhancement in affinity compared to [¹⁸F]-**2a** and accessible in high radiochemical yield and specific activity.¹³ Subsequent in vivo studies of [¹⁸F]-2b demonstrated this agent to possess several properties for molecular imaging of TSPO-expressing cancers.^{13,21}

In addition to the aryloxyanilides and pyrazolopyrimidines, pyridazinoindoles are another series of potent TSPO ligands, as represented by 7-chloro-*N*,*N*,5-trimethyl-4-oxo-3-phenyl-3,5-dihy-dro-4*H*-pyridazino[4,5-*b*]indole-1-acetamide (SSR180575, **3**).^{22,23} Developed originally by Sanofi-Aventis, the specificity and high-affinity of **3** for TSPO has prompted research in cardiovascular^{24,25} and renal pathologies,²⁶ as well as neurodegenerative indications,²³ inflammatory disorders,^{22,27-29} and HIV pathogenesis.³⁰

The goal of this study was to determine whether optimization of 3, specifically at the N3 position, would yield TSPO ligands with comparable affinity and potential to serve as PET imaging ligands. These experiments led to the synthesis of **3** in only four steps and the subsequent development of 7-chloro-N,N,5-trimethyl-4-oxo-3(6-fluoropyridin-2-yl)-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide (14), a novel pyridazinoindole TSPO ligand exhibiting binding comparable to **3** and structural features suitable for radiolabeling with fluorine-18 (¹⁸F). Radiofluorination of either the 2chloro (15) or 2-bromo (16) precursor gave 7-chloro-N,N,5-trimethyl-4-oxo-3(6-[¹⁸F]fluoropyridin-2-yl)-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide ($[^{18}F]$ -14), which was subsequently evaluated in vivo in a preclinical model of glioma (C6). [¹⁸F]-14 exhibited modest accumulation in normal brain, yet robust accumulation in tumor tissue, which facilitated excellent imaging contrast. [¹⁸F]-14 was fully displaceable by administration of nonradioactive 14 halfway through the PET scan. Overall, these studies illuminate [¹⁸F]-**14** as a promising, novel PET ligand for evaluating TSPO expression in gliomas and potentially other solid tumors and diseases.

The original synthesis of SSR180575 (**3**) remains a patented process at seven total steps.³¹ Moreover, the patented SAR studies of **3**

targeted four areas on the scaffold, the acetamide functionality at C1 and the N3, N5, and C7 positions of the tricyclic pyridazinoindole ring (Fig. 1).^{31,32} The synthesis developed and reported herein requires only four steps from a commercially available starting material (Scheme 1). A small library of pyridazinoindoles (Table 1) was assembled, with the point of divergence at the final condensation step with strategic aryl-hydrazines (**8**) (Scheme 1). The design of the library focused primarily on incorporation of fluorine onto an aromatic ring and potential substituents that would facilitate radiolabeling with ¹⁸F.

The overall synthetic methodology is presented in Scheme 1. Starting from a commercially available indole (**4**), deprotonation with sodium hydride in DMF, followed by treatment with methyl iodide, gave the desired N-methylated intermediate (**5**) (85%). Acylation of (**5**) at C3 was achieved using TiCl₄ and methyl chloro-3-oxopropanoate in dichloroethane at 40 °C for 15 h, which gave keto diester **6** (46%). The necessary *N*,*N*-dimethylamide moiety at C1 (**7**) was achieved through displacement of the methoxy group of (**6**) with dimethylamine in toluene and THF in a sealed tube at 110 °C for 15 h. Final condensation with phenylhydrazine (**8**, R = phenyl) gave the lead compound, SSR1805875 (**3**), in 32% yield. To date, this stands as the shortest reported synthesis of this particular TSPO ligand.

Diversification at the N3 position of **3** was achieved through condensation of key intermediate **7** with a series of monosubstituted aryl hydrazines (**8**) (31–50%). The hydrazines chosen focused upon variation of the endogenous N3-phenyl ring, with particular attention towards preliminary SAR and functional groups amenable to PET ligand development, namely the presence of a fluorine atom and groups that would facilitate radiolabeling with ¹⁸F through an *ipso*-type substitution. The groups explored included: a substituted phenyl ring (2-, 3-, 4-positions) (**9–12**); a 2-pyridyl ring (**13**); a substituted 2-pyridyl ring (**14–16**).

To evaluate binding to TSPO, radiometric binding assays were carried out with the compounds in a variety of athymic nude rat cell lysates (C6, heart, kidney) using *N*-(*sec*-butyl)-1-(2-chlorophenyl)-*N*-methyl-[³H]-isoquinoline-3-carboxamide ([³H]PK11195).^{11,12} For central benzodiazepine receptor (CBR) binding, radioligand displacement was carried out against [³H]flunitrazepam in healthy, rat brain lysate. Affinities are expressed as $K_i \pm S.E.M.$ (pM) in Table 1. All experiments were performed in triplicate.

Of the eight analogs synthesized, seven proved extremely potent in all three lysates, with K_i values comparable to those of the parent SSR180575 (**3**): in C6 lysate, 0.280–2.34 pM versus 1.23 pM for **3**; in heart 0.180–3.21 pM versus 0.762 pM for **3**; in kidney, 0.212–2.21 pM versus 0.596 pM for **3**. Only one analog, compound **13**, bearing a 2-pyridyl ring at N3, did not appreciably bind TSPO in any of the lysates. Interestingly, a portion of the compounds synthesized showed evidence of mixed (low, high) binding affinities. In C6 lysate, compounds **12** and **14** demonstrated high-affinity binding at 0.671 and 1.19 pM, and low-affinity binding at



Figure 1. Representative TSPO ligand scaffolds: Aryloxyanilide (1, PBR06); pyrazolopyrimidine (2a, DPA-714; 2b, VUIIS1008); pyridazinoindole (3, SSR180575).



Scheme 1. Synthetic methodology developed to generate SSR180575 (3) and a focused library of N3-substituted pyridazinoindoles (9-16).

Table 1Affinity of pyridazinoindoles



| Compd | R | C6 Glioma K_i^b (pM) | Heart K_i^b (pM) | Kidney K_i^b (pM) |
|-----------------------|--------------------|---------------------------------------|--------------------|---|
| 3 ^a | Ph | 1.23 ± 0.08 | 0.762 ± 0.15 | 0.596 ± 0.04 |
| 9 | 2-Fluorophenyl | 0.422 ± 0.06 | 0.591 ± 0.10 | 1.18 ± 0.04 |
| 10 | 3-Fluorophenyl | 0.280 ± 0.07 | 0.180 ± 0.02 | 0.212 ± 0.02 |
| 11 | 3-Nitrophenyl | 0.889 ± 0.2 | 1.18 ± 0.09 | 0.678 ± 0.2 |
| 12 | 4-Fluorophenyl | 0.671 ± 0.2 ; 3020 ± 1007^{d} | 0.877 ± 0.03 | 0.459 ± 0.03 ; 969 ± 752 ^d |
| 13 | 2-Pyridyl | 2409 ± 795.4 | 4936 ± 662.3 | 6796 ± 830.9 |
| 14 ^c | 3-Fluoro-2-pyridyl | $1.19 \pm 0.05; 1770 \pm 232.6^{d}$ | 3.21 ± 0.4 | 2.21 ± 0.4 |
| 15 | 3-Chloro-2-pyridyl | 2.34 ± 0.4 | 0.676 ± 0.08 | 0.495 ± 0.03 |
| 16 | 3-Bromo-2-pyridyl | 1.48 ± 0.2 | 0.281 ± 0.01 | 0.965 ± 0.02 |

^a SSR18075.

^b S.E.M versus [³H]PK11195.

^c Ki versus [³H]flunitrazepam in rat brain lysate >10 μM.

^d Mixed affinity binding. All lysates procured from athymic nude rats. All experiments performed in triplicate.

1770 and 3020 pM, respectively. Compound **12** demonstrated similar mixed binding in kidney lysate (0.459 and 969 pM), but not the heart. While multiple PK11195 TSPO binding sites have been reported and merit consideration,³³ recent research has also implicated a genetic polymorphism for such binding variations in the human brain.^{34,35} However, genetic sequencing of the C6 cell line from the specific clonal population used for this study confirmed its wild-type status. The mixed binding we observed could potentially be a result of overlapping points of interaction that the analogs and PK11195 possess for TSPO.

Overall, the modifications made to lead compound **3**, with the exception of **13**, were well tolerated. While substitution of the N3-phenyl ring with 2-pyridine did adversely affect binding across all three lysates, comparable biological activity was regained with halogen substitution at the 3-position of the ring (**14–16**). This influence on potency could be attributed to an electronic effect of the halogen atom and merits further consideration in future studies. Similarly, 2-, 3-, and 4-fluorosubstitution on the endogenous phenyl ring with fluorine (**9**, **10**, **12**, respectively) proved to minimally affect TSPO affinity, as did 4-nitro-substitution (**11**). This series of compounds are among the most potent ligands reported for

TSPO in C6 glioma (**1** K_i = 6170 pM;¹¹ **2a** K_i = 9730 pM;¹² **2b** K_i = 270 pM¹³). Moreover, in our lab, compound **14** represents a 1000-fold increase in potency over **2b**.

Of the synthesized series, the 3-fluoro analog **10** was initially considered the candidate PET tracer, particularly given its activity and ready availability of its 3-nitro precursor (**11**). However, effective substitution of a nitro group with ¹⁸F⁻ on a benzene ring requires a highly deactivated ring system, preferably with electron-withdrawing groups either *ortho* or *para* to the nitro moiety. Neither was the case for **11** as a precursor. Similar arguments could also be made for consideration of **9** or **12** as PET tracer candidates. Compound **14** was ultimately chosen as the candidate PET tracer, with **15** and **16** as possible precursors. The selectivity of **14** for TSPO over CBR was evaluated through displacement of [³H]flunitrazepam in rat cerebral cortex membranes (Table 1). The selectivity of **14** for TSPO over CBR was verified with [³H]flunitrazepam, which gave a $K_i > 10 \mu M$.

Isotopic labeling of **3** with both ¹¹C and ¹⁸F has been previously reported in the patent literature.³⁶ In the research literature, Thominiaux et al. reported ¹¹C labeling at the 5-methyl-pyridazino[4,5-*b*]indole ([*indole-N-methyl-*¹¹C]SSR180575) and *N*,*N*-

dimethylacetamide ([acetamide-N-methyl-¹¹C]SSR180575)³⁷ moieties. Within the context of radiochemical yield and purity, and vivo pharmacological properties, [indole-N-methyl-11C]in SSR180575 was advanced as a candidate for imaging neuroinflammation³⁷ and afforded higher image contrast when compared to the traditional isoquinoline [11C]PK11195 in a model of acute neuroinflammation (rat).³⁸ Moreover, competition studies demonstrated a high specific binding of [¹¹C]SSR180575 for TSPO.³⁸ However, as far as the authors are aware, no studies to date have been reported for the use of isotopically labeled SSR180575 for PET imaging in oncology. Since our goal was to explore 3 as a potential radiopharmaceutical lead for translation into preclinical cancer imaging studies, radiofluorination was deemed to be the most effective means to achieve this goal. Though useful in the research setting, the 20.4 min half-life of ¹¹C limits broader utility of the tracer (shipment to satellite locations, dynamic PET studies), thus making ¹⁸F (109.4 min half-life) an attractive alternative.

We initially applied microfluidic-radiolabeling approaches to elucidate stability and ascertain labeling feasibility of precursors 15 and 16. Using a commercial microfluidic module (NanoTek[®]) that enabled carefully controlled stoichiometry between [¹⁸F]⁻ and precursor at set temperatures (°C) with controllable reaction times (µL/min flow rates), we carried out multiple, small-scale, sequential radiolabelings in a relatively short amount of time, allowing rapid optimization of labeling conditions (Table 2). The information gathered with the NanoTek® module was used to better inform the transition to the GE TRACERlabTM FX_{F-N} module for larger, preclinical-scale productions. Using cyclotron-generated ${}^{18}F^-$ and $K^+-K_{2,2,2}/K_2CO_3$ in anhydrous DMSO, a series of reaction temperatures (80-180 °C) at a transfer rate of 40 µL/min was investigated, with product formation monitored by radio-TLC for % $^{18}\mbox{F-incorporation}$ (Table 2). For the chloro precursor (15), product formation was observed at 180 °C (1.41%) at a transfer rate of 40 μ L/min. Maintaining a reaction temperature of 180 °C and decreasing the transfer rate to 14 µL/min gave modest incorporation (5.2%, Table 2, entry 3). Similar results were obtained using precursor 16 (Table 2, entry 6). Despite modest yields, the data generated from these experiments also highlighted the thermal stability (up to 180 °C) of both 15 and 16, verified by HPLC of crude reaction mixtures. Bromo-precursor 16 was ultimately chosen going forward given its optimal chromatographic resolution from the final product ([¹⁸F]-14). These observations provided a confident basis to pursue the radiolabeling reaction in a sealed system at 180 °C for a longer period of time.

Adaptation of these reaction conditions to large-scale box productions enabled preclinical production of $[^{18}F]$ -**14** in the GE TRACERlabTM FX_{F-N} module with labeling conditions of 165 °C for 20 min. A lowering of the reaction temperature from 180 to 165 °C was deemed necessary due to the limitations of heating reliability at such an extreme temperature using the TRACERlabTM platform. Purification of $[^{18}F]$ -**14** was carried out with preparative HPLC in 45% ethanol and 55% water. The retention time of $[^{18}F]$ -**14** was 23–28 min according to gamma detection and corresponded to the UV retention time of nonradioactive **14**. Radiochemical purity was consistently greater than 99% (n = 9), with decay-corrected yields ranging from 9.3–19.3% and specific activities as high as 5559 Ci/mmol (206 TBq/mmol) (n = 9). However, the apparent specific activity was diminished using 42.5% ethanol and 57.5% water, despite the longer retention time.

The in vivo performance of [18F]-14 was evaluated in gliomabearing (C6), male Wistar rats using microPET imaging, with a typical study shown in Figure 2. MRI (T₂-weighted) was used to localize tumors and for registration of anatomical features with PET (Fig. 2A).^{11,12,18} Dynamic PET imaging with [¹⁸F]-**14** illustrated that the majority of tracer accumulation in the brain was localized to the tumor, with modest accumulation that exceeded plasma in contralateral, non-tumor brain (Fig. 2B and C). The tumor-selective characteristics of [¹⁸F]-14 afforded excellent imaging contrast between tumor and contralateral tissue. Figure 2G illustrates time-activity curves (TACs) typical of representative studies for tumor (blue), normal brain (green), and plasma (red) over a 90-min dynamic acquisition. After an initial spike in radioactivity consistent with tracer injection and rapid distribution, [¹⁸F]-14 quickly cleared the plasma (red). We found that [¹⁸F]-**14** accumulation in the tumor (blue), relative to normal brain (green), reached a tumor-to-normal brain ratio greater than 10:1. Preliminary radio-TLC analysis of plasma samples (2, 12, 30, 60 min) taken during the scan (n = 2) suggested minimal tracer metabolism over the 60 min (% parent at 60 min >90%).

To validate the PET, imaging-matched brains were processed for *post-mortem* staining and immunohistochemistry for TSPO. Ex vivo histological analysis correlated well with PET imaging data, with close agreement between tumor tissue (H&E, Fig. 2E), elevated TSPO expression (immunohistochemistry, Fig. 2F), and tumor accumulation of [¹⁸F]-**14** (Fig. 2D).

To evaluate the in vivo TSPO specificity of [¹⁸F]-**14**, we performed displacement studies in C6-bearing rats using the nonradioactive analog (**14**). As shown in the TAC in Figure 2H, during the dynamic PET study, a bolus (IV) infusion of nonradioactive **14**



 Table 2

 Initial radiofluorination of precursors 15 and 16 using microfluidics

| Run | X | Temp (°C) | Transfer rate (µL) | RCY (%) |
|-----|----|-----------|--------------------|---------|
| 1 | Cl | 140 | 40 | 0 |
| 2 | Cl | 160 | 40 | 0 |
| 3 | Cl | 180 | 14 | 5.2 |
| 4 | Br | 140 | 40 | 0 |
| 5 | Br | 160 | 40 | 1 |
| 6 | Br | 180 | 60 | 7 |

*Precursors **15** and **16** stable up to 180 °C.



Figure 2. Imaging of preclinical glioma using [¹⁸F]-**14.** (A) T₂-weighted MRI (*coronal*). (B) Fused MRI-PET (*coronal*). (C) Dynamic PET (*coronal*). (D) Dynamic PET (*axial*). (E) H&E histology. (F) TSPO immunohistochemistry. (G) Typical dynamic PET TAC. (H) Displacement study PET TAC.

(10 mg/kg) was administered approximately 30 min after injection of [¹⁸F]-**14**. Summation of the first 30 min of the PET scan prior to injection of cold **14** (0–30 min) demonstrated typical accumulation characteristics of [¹⁸F]-**14**. However, summation of the final 30 min of the PET scan (30–60 min) demonstrated significant displacement of [¹⁸F]-**14** from tumor tissue (blue). TAC analysis demonstrated that after injection of **14**, tumor binding was reduced to approximately 40% of the peak tumor uptake. During tumor displacement, we observed a minor influx of tracer into normal brain (green). The displaced [¹⁸F]-**14** then rapidly cleared the normal brain and entered the plasma, subsequently elevating plasma (red) radioactivity. These studies suggest a level of displaceable binding indicative of a high degree of specific binding and reversibility of [¹⁸F]-**14** to TSPO in tumor tissue.

In this work, we report the shortest published synthesis of the pyridazinoindole TSPO ligand SSR180575 (**3**) to date. Initial SAR exploration at the N3 position of 3 provided a series of analogs of comparable potency, one of which (14) could be adapted into a potential PET imaging tracer ([¹⁸F]-**14**). Subsequent preclinical studies illuminated [¹⁸F]-**14** as a promising, novel TSPO PET ligand for imaging glioma. Compared to previous TSPO PET ligands in oncology, the first generation ligand [¹¹C]PK11195³⁹ and the second generation ligands [¹⁸F]PBR06,¹⁹ [¹⁸F]DPA-714,¹² and [¹⁸F]VUIIS1008,^{13,21} [¹⁸F]-**14** has demonstrated improved binding affinity and in vivo imaging characteristics. These advantages, in addition to the in vivo stability and high signal-to-noise achieved between tumor and surrounding normal brain, suggest the potential of this PET ligand for detection of TSPO-expressing tumors in

the brain and neuroinflammation. Future head-to-head comparisons between this tracer and emerging, potent TSPO ligands^{13,21} are underway, as well as exploration of other promising applications in oncology, neuroinflammation, and other diseases.

Acknowledgment

We acknowledge funding from the National Institutes of Health (K25 CA127349, P50 CA128323, S10 RR17858, U24 CA126588, 1R01 CA163806, P50 CA095103, P30 DK058404), The Kleberg Foundation, and The Lustgarten Foundation. Dr. M. Noor Tantawy, George H. Wilson, and Dr. Daniel Colvin are acknowledged for support of the imaging studies.

Supplementary data

Supplementary data (analytical results for all compounds; methods; supplemental figures) associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.bmcl.2014.07.091.

References and notes

- 1. Dhermain, F. G.; Hau, P.; Lanfermann, H.; Jacobs, A. H.; van den Bent, M. J. Lancet Neurol. 2010, 9, 906.
- Rheims, S.; Rubi, S.; Bouvard, S.; Bernard, E.; Streichenberger, N.; Guenot, M.; Le Bars, D.; Hammers, A.; Ryvlin, P. Neurooncology 2014.
- Jansen, N. L.; Suchorska, B.; Wenter, V.; Eigenbrod, S.; Schmid-Tannwald, C.; Zwergal, A.; Niyazi, M.; Drexler, M.; Bartenstein, P.; Schnell, O.; Tonn, J. C.; Thon, N.; Kreth, F. W.; Ia Fougere, C. J. Nucl. Med. 2014, 55, 198.

- Schwarzenberg, J.; Czernin, J.; Cloughesy, T. F.; Ellingson, B. M.; Pope, W. B.; Grogan, T.; Elashoff, D.; Geist, C.; Silverman, D. H.; Phelps, M. E.; Chen, W. Clin. Cancer Res. 2014, 20, 3550.
- 5. Goldman, S.; Pirotte, B. J. Methods Mol. Biol. 2011, 727, 291.
- la Fougere, C.; Suchorska, B.; Bartenstein, P.; Kreth, F. W.; Tonn, J. C. Neurooncology 2011, 13, 806.
 Pirotte B.: Coldman S.: Massager N.: David P.: Wikler D.: Vandesteene A.:
- Pirotte, B.; Goldman, S.; Massager, N.; David, P.; Wikler, D.; Vandesteene, A.; Salmon, I.; Brotchi, J.; Levivier, M. J. Nucl. Med. 2004, 45, 1293.
- Deane, N. G.; Manning, H. C.; Foutch, A. C.; Washington, M. K.; Aronow, B. J.; Bornhop, D. J.; Coffey, R. J. *Mol. Cancer Res.* 2007, 5, 341.
- Wyatt, S. K.; Manning, H. C.; Bai, M.; Bailey, S. N.; Gallant, P.; Ma, G.; McIntosh, L.; Bornhop, D. J. Mol. Imaging Biol. 2010, 12, 349.
- Manning, H. C.; Goebel, T.; Thompson, R. C.; Price, R. R.; Lee, H.; Bornhop, D. J. Bioconjug. Chem. 2004, 15, 1488.
- Buck, J. R.; McKinley, E. T.; Hight, M. R.; Fu, A.; Tang, D.; Smith, R. A.; Tantawy, M. N.; Peterson, T. E.; Colvin, D.; Ansari, M. S.; Baldwin, R. M.; Zhao, P.; Guleryuz, S.; Manning, H. C. J. Nucl. Med. 2011, 52, 107.
- Tang, D.; Hight, M. R.; McKinley, E. T.; Fu, A.; Buck, J. R.; Smith, R. A.; Tantawy, M. N.; Peterson, T. E.; Colvin, D. C.; Ansari, M. S.; Nickels, M.; Manning, H. C. J. Nucl. Med. 2012, 53, 287.
- Tang, D.; McKinley, E. T.; Hight, M. R.; Uddin, M. I.; Harp, J. M.; Fu, A.; Nickels, M. L.; Buck, J. R.; Manning, H. C. J. Med. Chem. 2013, 56, 3429.
- Papadopoulos, V.; Baraldi, M.; Guilarte, T. R.; Knudsen, T. B.; Lacapere, J. J.; Lindemann, P.; Norenberg, M. D.; Nutt, D.; Weizman, A.; Zhang, M. R.; Gavish, M. Trends Pharmacol. Sci. 2006, 27, 402.
- Varrone, A.; Mattsson, P.; Forsberg, A.; Takano, A.; Nag, S.; Gulyas, B.; Borg, J.; Boellaard, R.; Al-Tawil, N.; Eriksdotter, M.; Zimmermann, T.; Schultze-Mosgau, M.; Thiele, A.; Hoffmann, A.; Lammertsma, A. A.; Halldin, C. *Eur. J. Nucl. Med. Mol. Imaging* **2013**, 40, 921.
- Suridjan, I.; Rusjan, P. M.; Voineskos, A. N.; Selvanathan, T.; Setiawan, E.; Strafella, A. P.; Wilson, A. A.; Meyer, J. H.; Houle, S.; Mizrahi, R. *Neuroimage* 2013.
- Takano, A.; Piehl, F.; Hillert, J.; Varrone, A.; Nag, S.; Gulyas, B.; Stenkrona, P.; Villemagne, V. L.; Rowe, C. C.; Macdonell, R.; Tawil, N. A.; Kucinski, T.; Zimmermann, T.; Schultze-Mosgau, M.; Thiele, A.; Hoffmann, A.; Halldin, C. *EJNMMI Res.* **2013**, *3*, 30.
- 18. Batarseh, A.; Papadopoulos, V. Mol. Cell Endocrinol. 2010.
- 19. Buck, J. R.; Saleh, S.; Uddin, M. I.; Manning, H. C. Tetrahedron Lett. 2012, 53, 4161.
- Powell, A. E.; Vlacich, G.; Zhao, Z. Y.; McKinley, E. T.; Washington, M. K.; Manning, H. C.; Coffey, R. J. Am. J. Physiol. 2014, 307, G16.
- Tang, D.; Nickels, M. L.; Tantawy, M. N.; Buck, J. R.; Manning, H. C. Mol. Imaging Biol. 2014.

- Bribes, E.; Bourrie, B.; Esclangon, M.; Galiegue, S.; Vidal, H.; Casellas, P. Eur. J. Pharmacol. 2002, 452, 111.
- 23. Ferzaz, B.; Brault, E.; Bourliaud, G.; Robert, J. P.; Poughon, G.; Claustre, Y.; Marguet, F.; Liere, P.; Schumacher, M.; Nowicki, J. P.; Fournier, J.; Marabout, B.; Sevrin, M.; George, P.; Soubrie, P.; Benavides, J.; Scatton, B. J. Pharmacol. Exp. Ther. 2002, 1067, 301.
- Leducq, N.; Bono, F.; Sulpice, T.; Vin, V.; Janiak, P.; Fur, G. L.; O'Connor, S. E.; Herbert, J. M. J. Pharmacol. Exp. Ther. 2003, 306, 828.
- Vin, V.; Leducq, N.; Bono, F.; Herbert, J. M. Biochem. Biophys. Res. Commun. 2003, 310, 785.
- Kunduzova, O. R.; Escourrou, G.; De La Farge, F.; Salvayre, R.; Seguelas, M. H.; Leducq, N.; Bono, F.; Herbert, J. M.; Parini, A. J. Am. Soc. Nephrol. 2004, 15, 2152.
- 27. Galiegue, S.; Tinel, N.; Casellas, P. Curr. Med. Chem. 2003, 10, 1563.
- 28. Bribes, E.; Galiegue, S.; Bourrie, B.; Casellas, P. Immunol. Lett. 2003, 85, 13.
- 29. Bribes, E.; Bourrie, B.; Casellas, P. Immunol. Lett. 2003, 88, 241.
- Leducq-Alet, N.; Vin, V.; Savi, P.; Bono, F. Biochem. Biophys. Res. Commun. 2010, 399, 475.
- Ferzaz, B.; Benavides, J.; Marguet, F.; Froissant, J.; Marabout, B.; Evanno, Y.; Sevrin, M.; Janiak, P.; Organization, W. I. P., Ed.; Sanofi-Synthelabo: France, 2000, p 32.
- Evanno, Y.; Dubois, L.; Sevrin, M.; Marguet, F.; Froissant, J.; Bartsch, R.; Gille, C.; Organization, W. I. P., Ed.; Synthelabo S. A.: France, 1999.
- 33. Scarf, A. M.; Kassiou, M. J. Nucl. Med. 2011, 52, 677.
- Owen, D. R.; Yeo, A. J.; Gunn, R. N.; Song, K.; Wadsworth, G.; Lewis, A.; Rhodes, C.; Pulford, D. J.; Bennacef, I.; Parker, C. A.; StJean, P. L.; Cardon, L. R.; Mooser, V. E.; Matthews, P. M.; Rabiner, E. A.; Rubio, J. P. J. Cereb. Blood Flow Metab. 2012, 32, 1.
- Yoder, K. K.; Nho, K.; Risacher, S. L.; Kim, S.; Shen, L.; Saykin, A. J. J. Nucl. Med. 2013, 54, 1320.
- Benavides, J.; Boutin, H.; Castel, M.-N.; Damont, A.; Dolle, F.; Hantraye, P.; Marguet, F.; Rooney, T.; Rivron, L.; Tavitian, B.; Thominiaux, C.; Sanofi-Aventis, Fr.; Commissariat a l'Energie Atomique C.E.A.: France, 2010, p 40.
- Thominiaux, C.; Damont, A.; Kuhnast, B.; Demphel, S.; Helleix, S. L.; Boisnard, S.; Rivron, L.; Chauveau, F.; Boutin, H.; Camp, N. V.; Boisgard, R.; Roy, S.; Allen, J.; Rooney, T.; Benavides, J.; Hantraye, P.; Tavitian, B.; Dolle, F. J. Labelled Compd. Radiopharm. 2010, 53, 767.
- Chauveau, F.; Boutin, H.; Van Camp, N.; Thominiaux, C.; Hantraye, P.; Rivron, L.; Marguet, F.; Castel, M. N.; Rooney, T.; Benavides, J.; Dolle, F.; Tavitian, B. Eur. J. Nucl. Med. Mol. Imaging 2011, 38, 509.
- Starostarubinstein, S.; Ciliax, B. J.; Penney, J. B.; Mckeever, P.; Young, A. B. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 891.